The company uses atmospheric pressure-based ion mobility spectrometry to analyze biologically relevant native conformations of proteins, protein complexes, and nucleic acid modalities, enabling researchers to avail comparability studies to create an antibody biotherapeutic drug. IonDX's innovative and patented ion mobility technology aims to help scientists analyze the higher order structure of proteins and biotherapeutics in a high throughput manner. The operator of a life sciences instrumentation company intends to focus on developing biotherapeutic analytical services to support accelerated drug development.